|
Media event:
|
Media event on the latest data from the RE-LY® trial, recent sub-group analyses and the implications for guidelines and daily practice.
|
|---|---|
|
Venue:
|
ESC Industry Press Conference Room
Monday, 30 August 2010
|
Dabigatran etexilate: Challenging the approach to stroke prevention in atrial fibrillation
Background information for medical media outside the US only
Disclaimer
The content of the website has been cleared by Boehringer Ingelheim GmbH in compliance with the legal provisions applicable for German companies. Such provisions vary from country to country and can have an impact on the information we can provide to you.
Thus, please contact us directly in case further information is requested which takes into account the framework in your home country.
contact
